智通财经APP讯,贝康医疗-B(02170)公布,董事会已审议及批准建议实施H股全流通,以转换合共约1.91亿股公司未上市股份为公司H股。待取得所有相关批准及╱或备案(包括中国证监会的备案通知及联交所的批准)并符合所有适用法律、法规及规则后,该等未上市股份将转换为H股,且公司将申请批准该等H股于联交所主板上市及买卖。
智通财经APP讯,贝康医疗-B(02170)公布,董事会已审议及批准建议实施H股全流通,以转换合共约1.91亿股公司未上市股份为公司H股。待取得所有相关批准及╱或备案(包括中国证监会的备案通知及联交所的批准)并符合所有适用法律、法规及规则后,该等未上市股份将转换为H股,且公司将申请批准该等H股于联交所主板上市及买卖。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.